Delving into the Latest Updates on Olanzapine with Synapse

Overview

Basic Info

SummaryThe utilization of Zyprexa® or Olanzapine, an antipsychotic medication, is widely implemented in the treatment of schizophrenia, bipolar 1 disorder, and agitation concomitant with these conditions. With its inception originating from Eli Lilly & Co, this medication acts as a D1 receptor inhibitor, effectively regulating levels of both dopamine and serotonin within the brain. Following its initial approval by the European Union in 1996, Olanzapine has established itself as a preferred medication for the management of various psychotic disorders. Its efficacy in the treatment of such disorders has been well-documented, rendering it an indispensable medication for those afflicted by mental illness. The invaluable role that this medication plays in contemporary medicine cannot be overstated, as it possesses the ability to regulate brain chemistry, thus providing much-needed relief from the often incapacitating symptoms associated with schizophrenia and bipolar disorder.

Drug Type

Small molecule drug

Synonyms

2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine, Olanzapin, olanzapine LAI

+ [42]

Target

5-HT2A receptor x 5-HT2C receptor x D2 receptor x HTR3

Action

antagonists

Mechanism

5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), 5-HT2C receptor antagonists(Serotonin 2c (5-HT2c) receptor antagonists), 5-HT3 receptor antagonists(5-hydroxytryptamine receptors, ionotropic (HTR3) antagonists)

Therapeutic Areas

Nervous System DiseasesOther DiseasesCongenital Disorders

Active Indication

Chemotherapy-induced nausea and vomitingAgitationDepressive Disorder+ [8]

Inactive Indication

Anorexia NervosaBorderline Personality DisorderBronchopulmonary Dysplasia+ [8]

Originator Organization

Eli Lilly & Co.

Active Organization

Teva Pharmaceuticals Europe BVGlenmark Arzneimittel GmbH

Eli Lilly & Co.

+ [7]

Inactive Organization

Apotex Europe BV

Qilu Pharmaceutical Co., Ltd.PLIVA Croatia Ltd.

+ [8]

License Organization

Teva Pharmaceutical Industries Ltd.

Eli Lilly & Co.

Starton Therapeutics, Inc.

+ [4]

Drug Highest PhaseApproved

First Approval Date

European Union (27 Sep 1996),

Bipolar DisorderManiaSchizophrenia

RegulationPriority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC17H20N4S

InChIKeyKVWDHTXUZHCGIO-UHFFFAOYSA-N

CAS Registry132539-06-1

The objective of this study is to respond to frequent requests from patients who wish to reduce or even stop their antipsychotic treatment once they have achieved clinical stability. Psychiatrists are reluctant to respond to these requests because the method for safely reducing or stopping antipsychotic treatment remains poorly understood.
The investigators want to verify the existence of an interaction between treatment strategy and psychotic phenotype (cycloid psychosis vs. non-CP), i.e., in terms of functional remission, the benefit of the dose reduction strategy compared to the maintenance strategy will be greater in the CP group than in the non-CP group.
To this end, patients will be randomly assigned to four groups based on their phenotype and treatment strategy (CP-dose reduction; CP-dose maintenance; non-CP-dose reduction; and non-CP-dose maintenance).
Several hospitals throughout France are participating in this study, in which a random draw (called randomization) will be conducted to determine whether the physician will propose reducing the antipsychotic dose or maintaining it at the same dose for the patient.
Patients included in this study will be adults aged 18 to 60 who have been diagnosed with a schizophrenic spectrum disorder (SS): schizophrenia, schizophreniform disorder, schizoaffective disorder, or brief psychotic episode.
The antipsychotics studied are:
* second-generation antipsychotics: amisulpride, aripiprazole, olanzapine, quetiapine, risperidone;
* first-generation antipsychotics: chlorpromazine, flupentixol, haloperidol, levomepromazine, loxapine, pipotiazine, zuclopenthixol.
288 patients will be included and followed for 24 months. The inclusion period is 48 months.
Fourteen follow-up visits are planned, every month for four months and then every two months. During these visits, self-questionnaires or cognitive tests will have to be completed by the patient, the caregiver, and/or the treating psychiatrist.
Three blood samples will be taken at inclusion, at 6 months, and at the end of the study, in particular to measure the level of medication in the blood.

Start Date01 Oct 2026

Sponsor / Collaborator

Les Hopitaux Universitaires de Strasbourg

NCT07841210

/ Active, not recruitingPhase 2IIT

An Exploratory Study of Fosrolapitant and Palonosetron Hyerocthoride for the Prevention of Nausea and Vomiting Induced by Highly Emetogenic ADC Therapy in Patients With Solid Tumors

This study aims to evaluate the efficacy and safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in preventing nausea and vomiting induced by highly emetogenic antibody-drug conjugate (ADC) therapy in patients with solid tumors. A total of 60 patients are planned to be enrolled and divided into two groups: Group A will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone plus Olanzapine, and Group B will receive Fosrolapitant and Palonosetron Hydrochloride for Injection plus Dexamethasone.

Start Date14 Sep 2026

Sponsor / Collaborator

Wuhan Xiehe Hospital Tower

[+2]

100 Clinical Results associated with Olanzapine

Login to view more data

100 Translational Medicine associated with Olanzapine

Login to view more data

100 Patents (Medical) associated with Olanzapine

Login to view more data

10,235

Literatures (Medical) associated with Olanzapine

01 Mar 2027·Value in Health Regional Issues

Cost-Effectiveness Analysis of Anamorelin and Olanzapine for Cancer Cachexia in Non-Small Cell Lung Cancer Patients in Japan

Article

Author: Nishikawa, Tatsuya ; Kashiwa, Munenobu

OBJECTIVES:

Cancer cachexia significantly impacts quality of life and prognosis in patients with non-small cell lung cancer. Anamorelin and olanzapine have demonstrated efficacy in improving appetite and body weight in clinical trials. However, their cost-effectiveness within the Japanese healthcare system is unclear. This study assesses the cost-effectiveness of anamorelin and olanzapine for cancer cachexia in patients with non-small cell lung cancer from the perspective of Japanese healthcare payers.

METHODS:

A Markov model with 7 health states was developed using clinical trial data (ONO-7643-04 for anamorelin and OlAnCa for olanzapine) and real-world cost and survival data from the Japan Medical Data Center claims database. The time horizon was 60 months, with 4-week cycles (65 cycles). Costs and quality-adjusted life years (QALYs) were discounted at an annual rate of 2%. One-way and probabilistic sensitivity analyses were conducted using 1000 Monte Carlo simulations.

RESULTS:

The incremental cost-effectiveness ratios were 7 405 419 Japanese yen (JPY)/QALY for anamorelin and 6 737 715 JPY/QALY for olanzapine compared with placebo. Both exceeded the willingness-to-pay threshold of 5 million JPY/QALY. At the 7.5 million JPY/QALY threshold, cost-effectiveness probabilities were 63.7% for anamorelin and 93.2% for olanzapine. One-way sensitivity analysis identified utility values and healthcare costs as the most influential parameters.

CONCLUSIONS:

Both anamorelin and olanzapine exceeded conventional cost-effectiveness thresholds in Japan. Given the limitations of pharmacotherapy in improving physical function, multimodal cachexia management incorporating nutritional counselling, exercise therapy, and rehabilitation warrants consideration.

01 Dec 2026·JOURNAL OF AFFECTIVE DISORDERS

Early metabolic and gut microbiota alterations during antipsychotic‑lithium treatment in acute bipolar mania: A prospective follow-up study

Article

Author: Sun, Chen ; Han, Wei-Jian ; Zhang, Xin ; Yi, Lei

OBJECTIVE:

To investigate early metabolic changes, gut microbiota alterations, and the correlations between key bacterial genera and metabolic indices in patients with bipolar disorder experiencing manic episodes who were treated with different antipsychotics combined with lithium carbonate.

METHODS:

This prospective observational follow-up study enrolled inpatients with bipolar disorder experiencing manic episodes who were medication-free at baseline. Participants were assigned according to treatment regimen into four groups: olanzapine combined with lithium carbonate, risperidone combined with lithium carbonate, aripiprazole combined with lithium carbonate, and lithium carbonate monotherapy. Metabolic parameters, including body weight, body mass index, waist circumference, fasting plasma glucose, triglycerides, and high-density lipoprotein cholesterol, were measured at baseline (T0), week 4 (T4), week 8 (T8), and week 12 (T12). Fecal samples were collected at T0 and T12, and gut microbiota composition was analyzed using 16S rRNA gene sequencing. Longitudinal changes in metabolic indices, α- and β-diversity of the gut microbiota, and genus-level differences in bacterial abundance were compared among groups. Spearman's rank correlation analysis was used to assess associations between changes in key bacterial genera and changes in metabolic parameters.

RESULTS:

A total of 80 patients were enrolled, and 68 completed the 12-week follow-up, with an overall dropout rate of 15.0%. From T0 to T12, changes in metabolic parameters differed significantly among the four groups (all P < 0.001). The olanzapine plus lithium carbonate group showed the most pronounced metabolic changes, followed by the risperidone plus lithium carbonate group, whereas changes were less marked in the aripiprazole plus lithium carbonate group and the lithium monotherapy group. α-diversity analysis showed that the Shannon and Simpson indices significantly increased from baseline to week 12 in the olanzapine/risperidone plus lithium carbonate group (both P < 0.05), whereas no significant changes were observed in the other two groups. β-diversity analysis indicated significant shifts in gut microbial community structure after treatment in the olanzapine and risperidone combination groups, while no significant changes were detected in the aripiprazole combination group or the lithium monotherapy group. Spearman correlation analysis showed that the change in centered log-ratio-transformed abundance of Collinsella was negatively correlated with changes in HDLC, whereas the change in Bifidobacterium abundance was positively correlated with changes in HDLC. The change in Blautia abundance was positively correlated with changes in triglycerides, while the change in Faecalibacterium abundance was negatively correlated with changes in BMI.

CONCLUSION:

Different antipsychotics combined with lithium carbonate were associated with distinct early metabolic burdens and gut microbiota alterations in patients with bipolar disorder experiencing manic episodes. Changes in gut microbiota composition were correlated with changes in metabolic indices, suggesting that the gut microbiota may be involved in the development of early antipsychotic-associated metabolic abnormalities.

01 Dec 2026·NEUROPHARMACOLOGY

Protective effects of central leptin on whole-body energy homeostasis following acute olanzapine exposure

Article

Author: Imami, Ali Sajid ; Wright, David C ; Hahn, Margaret K ; Hamoud, Abdul-Rizaq ; Prevot, Thomas D ; Baranowski, Bradley J ; Jeromson, Stewart ; Asgariroozbehani, Roshanak ; Mccullumsmith, Robert E ; Singh, Raghunath ; Remington, Gary ; Bernardo, Ashley ; Agarwal, Sri Mahavir ; Pereira, Sandra ; Wu, Sally ; Giacca, Adria

Antipsychotics represent mainstay treatment of schizophrenia and are also prescribed on- and off-label in other severe mental illnesses. Newer antipsychotic use is associated with severe metabolic side effects such as obesity and type 2 diabetes. Leptin is a hormone secreted by adipose tissue, and it acts on the brain to decrease body weight by reducing food intake and stimulating energy expenditure. Leptin also improves glucose and lipid metabolism. In this study, we examined the short-term impact of olanzapine, a commonly used second-generation antipsychotic, on the central leptin-mediated regulation of energy balance, glucose and lipid metabolism, and hypothalamic kinase activity. Male SD rats were given an acute intracerebroventricular (ICV) injection of either leptin or vehicle, combined with subcutaneous olanzapine or vehicle. As expected, ICV leptin decreased food intake and, importantly, olanzapine did not block this effect. Administration of leptin, olanzapine, or their combination reduced the average respiratory exchange ratio (RER) during the light-cycle, indicating increased fat oxidation. In the dark-cycle, leptin decreased the average RER regardless of olanzapine administration, and in the presence of leptin, olanzapine did not affect the average RER. Olanzapine treatment produced transient glucose intolerance during the IPGTT, an effect no longer observed with leptin co-treatment, though no significant differences in AUC, fasting serum glucose, insulin, or HOMA-IR were observed between any groups. Olanzapine and leptin treatment differentially activated hypothalamic kinases. In conclusion, the regulation of food intake and fuel preference by central leptin remains intact despite acute olanzapine administration, and leptin may transiently attenuate olanzapine-induced glucose intolerance.

235

News (Medical) associated with Olanzapine

17 Oct 2026

·healthcare-digital.com

Stryker, Viatris, Flo, Teva, J&J: This Week in Healthcare

Spencer Stiles (left) will replace current CEO Kevin Lobo (right) from 1 January 2027. Credit: Stryker This week's top stories include Stryker's CEO change, Viatris' pain management deal, J&J's Q3 earnings and Flo and Google's femtech partnership 1. Stryker CEO Change: Spencer Stiles to Replace Kevin Lobo After 14 years at Stryker 's helm, during which time company revenue tripled, Kevin Lobo is stepping down as CEO and will begin his transition to the Executive Chair position. Spencer Stiles, who has spent nearly three decades at the US medtech firm, will replace Kevin. Most recently, Spencer was the company's COO, a position he only assumed in January 2026. Stryker's CEO succession process is already underway but will formally be completed on 1 January 2027. On LinkedIn following the announcement, Spencer writes: “It is a tremendous privilege to lead a company with such a rich history, exceptional culture, and purpose-driven mission. I am grateful to Kevin and our Board for their trust and confidence, and I am energised by the opportunity and responsibility to build on the strong foundation that has made Stryker a global leader in medical technology. “Throughout my career at Stryker, I have seen firsthand what sets our company apart: our talented people, our unwavering commitment to customers and our relentless focus on innovation.” 2. Viatris to Acquire Pacira in US$1.65bn Pain Management Deal Central to Viatris’ decision to acquire Pacira is the opportunity to strengthen its position in non-opioid pain management. Credit: Viatris In the latest pharmaceutical industry deal, Viatris has announced plans to acquire Pacira BioSciences , a specialist in innovative non-opioid pain therapies. The deal, thought to be worth around US$1.65bn, adds Pacira’s two patented medicines, acute post-surgical pain therapy Exparel and osteoarthritis knee pain treatment Zilretta, to Viatris’ portfolio. Pacira generated approximately US$746m in total revenue during the last twelve months ended 30 June 2026. Viatris CEO Scott Smith says the acquisition marks a further step in the company’s strategy to strengthen its innovative medicines portfolio and drive sustainable growth. On LinkedIn, following the announcement, Scott writes that the deal “advances the strategy we laid out earlier this year – to drive our base business, fuel our innovative portfolio and modernise for sustainable growth. “Pacira brings established medicines, a promising pipeline and important capabilities that complement our existing portfolio and strengthen our position in non-opioid pain management, an area of significant unmet need. “Just as importantly, this is about where we go from here. We see an opportunity to build on these medicines and capabilities to support the continued growth of our innovative medicines portfolio.” 3. J&J Q3 Earnings: The US$100bn Revenue Goal Remains in Reach Johnson & Johnson has not tried to hide its 2026 revenue goal. The US$100bn figure – the highest in its 140-year history – has been a target referenced in its earnings reports throughout the year. On 13 October 2026, the pharmaceutical giant published its Q3 earnings report, beating earnings estimates and recording total quarterly sales of US$25.4bn. In doing so, Johnson & Johnson has also raised its full-year guidance to US$101.2bn. “Johnson & Johnson’s strong third-quarter performance and increased sequential growth reflect the accelerating momentum of our focused portfolio,” explains CEO Joaquin Duato . “This progress, together with strategic investments in high-growth areas, gives us clearer line of sight to double-digit growth by the end of the decade,” he continues. Central to Johnson & Johnson’s continued success in 2026 is, according to Chief Financial Officer Joseph Wolk, the company’s “diversified portfolio.” J&J's portfolio now includes 29 products and platforms generating at least US$1bn in annual sales, spanning its Innovative Medicine and MedTech divisions. 4. Google & Flo Health Launch Wearable Femtech Partnership The Flo app allows users to track, record and view personalised guidance at each stage of their menstrual cycle. Credit: Flo Google has announced its latest strategic partnership, which will see the global technology giant collaborate with leading women’s health platform Flo Health to integrate the Flo app into Google’s wearable technology. With more than 80 million monthly users, the Flo app offers in-depth menstrual cycle tracking enhanced by AI and data-backed predictions. From early 2027, consenting users will have the ability to connect Flo with Google Fitbit, the company’s wearable health platform. “By teaming up with Flo, together with our personalised coaching, research expertise and 24/7 tracking, we can help women understand their health in entirely new ways,” says Rishi Chandra, Vice President and General Manager of Google Health. The multi-year partnership accompanies Google’s strategic investment in Flo Health. The companies have outlined plans for future collaborative research into women’s healthcare, aiming to produce new insights into hormonal symptoms and chronic conditions. 5. Teva Wins FDA Approval For Schizophrenia Innovation As World Mental Health Month draws global support for people with mental health conditions, healthcare providers are focusing on patient-centric drug innovation to provide a wider range of comfortable, accessible treatment options. The FDA approval of Weltruza, produced by leading generic pharmaceutical provider Teva, signifies a milestone within schizophrenia treatment. Teva describes Weltruza as the first once-monthly subcutaneous olanzapine formulation for adults with schizophrenia: combining the antipsychotic with long-acting injectable technology, it offers an alternative to daily oral medicines, which patients can face difficulty adhering to. “I’m incredibly proud of our R&D team and everyone across Teva who helped make this possible,” writes Eric A. Hughes, CMO and Head of R&D at Teva, on LinkedIn. “I’m especially grateful to the patients who participated in our clinical trials and the investigators who partnered with us along the way.” For Teva, Weltruza’s impending rollout represents a significant strategic achievement as the pharmaceutical company pivots towards developing its pipeline of innovative medicines. Company portals Flo Health Google Johnson & Johnson Pacira BioSciences Stryker Teva Pharmaceutical Viatris Executives Eric A. Hughes, MD, PhD Member Board of Directors Joaquin Duato Chairman of the Board and Chief Executive Officer Kevin Lobo Chair & CEO Rishi Chandra VP/GM for Health and Home Scott A. Smith Chief Executive Officer

Drug ApprovalExecutive ChangeAcquisition

16 Oct 2026

·www.fiercepharma.com

Inside Teva's Weltruza launch and Novo's GLP-1 strategy

In this week's episode of "The Top Line," we're looking at two companies building on recent successes and pursuing new opportunities in the pharmaceutical industry. From Teva's growing portfolio of innovative medicines to Novo's expanding reach in the GLP-1 market, both companies are looking to build on their momentum as they prepare for the next phase of growth. First, Fierce Pharma's Fraiser Kansteiner speaks with Christine Fox, Teva's executive vice president of U.S. commercial and head of its innovative medicines franchise, and Eric Hughes, M.D., Ph.D., executive vice president of global R&D and chief medical officer. They discuss the FDA's recent approval of Weltruza, a once-monthly injectable treatment for schizophrenia, lessons learned from the company's earlier rollout of Uzedy and how its growing portfolio of innovative medicines fits into its broader strategy. They also explain how Weltruza's formulation could help address unmet needs in schizophrenia treatment. Then, we turn to Novo and the expanding market for GLP-1 drugs. At Fierce Pharma Week in Philadelphia, Fierce Pharma's Zoey Becker sat down with Kevin Donahoe, Novo's vice president and head of diabetes therapy area marketing and patient solutions, to discuss how the popularity of GLP-1s is creating new opportunities to reach and educate patients. Their conversation covers Novo's evolving marketing strategy, lessons from the Wegovy pill launch and the company's outlook on the future of obesity treatment as more medicines enter the market. Teva debuts Weltruza in schizophrenia as much-hyped FDA nod for long-acting olanzapine arrives Teva saddles up as stalking horse bidder for bankrupt BioXcel’s neuroscience portfolio With Austedo at helm, Teva's impressive innovative drug sales signal company's successful metamorpho… No more Nordisk as Novo goes it alone amid rebranding push The Oral GLP-1 Tracker How drugmakers are tapping into the GLP-1 frenzy's unprecedented 'consumer overlay'

Drug Approval

15 Oct 2026

·www.businesswire.com

Medincell Brings Total Non-Dilutive Financing Secured Since July 2026 to €41.8 Million with an Additional €13.8 Million Loan

Medincell (Euronext Paris: MEDCL) today announced that it has secured an additional €13.8 million in non-dilutive financing from leading European commercial banks and Bpifrance. This additional financing follows the €28 million in non-dilutive bank financing announced in July 2026, bringing the total amount of non-dilutive financing secured since July 2026 to €41.8 million. The financing has been secured on market terms and does not include any equity-linked instruments, resulting in no dilution for existing shareholders. Financial Position Snapshot €84.8 million in cash and cash equivalents as of March 31, 2026 €41.8 million in non-dilutive financing secured since July 2026, including the financing announced today €23.2 million repaid to the EIB in July 2026, including €20 million of principal – representing 50% of the existing financing facility, plus related capitalized interest Medincell is a clinical- and commercial-stage innovation-driven biopharmaceutical company developing and licensing long-acting injectable treatments across multiple therapeutic areas. Our innovative treatments are designed to ensure adherence to medical prescriptions, enhance the effectiveness and accessibility of medicines, and reduce their environmental impact. UZEDY® and WELTRUZA™ are trademarks of Teva Pharmaceuticals. Medincell’s BEPO® technology is licensed to Teva as SteadyTeq™, a trademark of Teva Pharmaceuticals. The content above comes from the network. if any infringement, please contact us to modify.

100 Deals associated with Olanzapine

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00454	Olanzapine	N05AH03	DB00334

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Chemotherapy-induced nausea and vomiting	Japan	CHEPLAPHARM Arzneimittel GmbH	25 Dec 2017
Chemotherapy-induced nausea and vomiting	Japan	Eli Lilly & Co.	25 Dec 2017
Agitation	United States	CHEPLAPHARM Arzneimittel GmbH	19 Mar 2009
Depressive Disorder	United States	CHEPLAPHARM Arzneimittel GmbH	19 Mar 2009
Depressive Disorder, Treatment-Resistant	United States	CHEPLAPHARM Arzneimittel GmbH	19 Mar 2009
Bipolar and Related Disorders	China	Eli Lilly & Co.	01 Jan 2006
Bipolar I disorder	United States	CHEPLAPHARM Arzneimittel GmbH	30 Sep 1996
Bipolar Disorder	European Union	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Bipolar Disorder	Iceland	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Bipolar Disorder	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Bipolar Disorder	Norway	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	European Union	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	Iceland	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Mania	Norway	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	European Union	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	Iceland	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	Liechtenstein	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996
Schizophrenia	Norway	CHEPLAPHARM Arzneimittel GmbH	27 Sep 1996

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Solid tumor	Phase 3	China	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	01 Oct 2020
Vomiting	Phase 3	China	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	01 Oct 2020
Gambling	Phase 3	United States	Eli Lilly & Co.	01 Feb 2007
FOXG1 syndrome	Phase 3	Netherlands	Eli Lilly Group Ltd.	16 Nov 2006
Weight Gain	Phase 3	United States	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Brazil	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Israel	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Mexico	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	Russia	Eli Lilly & Co.	01 Nov 2006
Weight Gain	Phase 3	South Korea	Eli Lilly & Co.	01 Nov 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TCTR20251008001 (ESMO2026)	Phase 2	Chemotherapy-induced nausea and vomiting	164	Sublingual ODT olanzapine 5 mg	btwnbneovv(kyxglfnncb) = ylycspisou dtgbbqtbqw (ivwdsibnlu ) View more	Positive	23 Oct 2026
				IV metoclopramide 10 mg	btwnbneovv(kyxglfnncb) = xqzkiugrlp dtgbbqtbqw (ivwdsibnlu ) View more
NCT06175273 (POINT, CTgov)	Phase 2/3	Child Nutrition Disorders \| Neoplasms \| Muscular Atrophy	20	Standard of Care (Control)	prjdfzajmf(dtkrdkgsvn) = dwalgvapxx egjufkrihj (oyswelhogu, 1.0417) View more	-	08 Oct 2026
				Oral Nutrition Supplement (Oral Nutrition Supplements)	prjdfzajmf(dtkrdkgsvn) = couvqwqwml egjufkrihj View more
NCT05676294 (Pubmed \| Anesthesiology)	Phase 3	Nausea and vomiting	384	Olanzapine 5 mg + Olanzapine 5 mg Ondansetron	zlyvbmminn(sfapdxzgyq): Difference = 4.8 (95.0% CI, 2.0 - 7.6), P-Value = 0.001 View more	Positive	01 Oct 2026
				Placebo + Dexamethasone & Ondansetron
NCT05590923 (CTgov)	Phase 4	Chemotherapy-induced nausea and vomiting \| Nausea \| Vomiting	23	DEX (Dexamethasone) (DEX (Dexamethasone))	lzowspjhlg = dkdibpfimv afvxnsazre (xedmhxisoc, hebctrwvbd - rdkrhszsys) View more	-	02 Sep 2026
				OLA (Olanzapine) (OLA (Olanzapine))	lzowspjhlg = fvhywuozjg afvxnsazre (xedmhxisoc, ksxzzbwgem - wrvpudykpq) View more
NCT05676294 (CTgov)	Phase 2	Postoperative Nausea and Vomiting	398	Olanzapine (Olanzapine)	uifcpxxdbs(ixcopanhhj) = hxakuwuxad jmukgmbccm (nmzstlurfj, aqyqsgdutw - mofkywprxe) View more	-	16 Jul 2026
				Placebo (Placebo)	uifcpxxdbs(ixcopanhhj) = gwgjbylasn jmukgmbccm (nmzstlurfj, qpsmzrgrhk - fgzdytzabi) View more
NCT06253546 (CTgov)	Phase 1	Schizophrenia	24	TV44749 (Period 2 Cohort 1: TV44749 318 mg)	awcfmczbkl = zspkarprlc fgjepeeany (jnnfgktgqw, fvnfxecrzl - bdjwdjoriy) View more	-	30 Jun 2026
				TV44749 (Period 2 Cohort 2: TV44749 425 mg)	awcfmczbkl = ietahsymuo fgjepeeany (jnnfgktgqw, gohavdnvfg - gzlgelgcuc) View more
INPHOG-SUPP-22-03 (ASCO_Breakthrough2026)	Phase 3	Chemotherapy-induced nausea and vomiting	299	Dexamethasone, palonosetron, and fosaprepitant	rqfpyvzvca(nfkqzmkrwt) = deqeqqmtcw kodwmxjgcp (tvvskyjvhh ) View more	Non-inferior	25 Jun 2026
				Olanzapine, palonosetron, and fosaprepitant	rqfpyvzvca(nfkqzmkrwt) = boouoydudt kodwmxjgcp (tvvskyjvhh ) View more
ASCO2026	Not Applicable	Chemotherapy-induced nausea and vomiting	1,557	Olanzapine-based triple antiemetic regimens	altervpsdb(nriemzqdpp): RR = 1.09 (95.0% CI, 0.98 - 1.2) View more	Positive	29 May 2026
				Aprepitant-based triple antiemetic regimens
ASCO2026	Not Applicable	Radiation-induced nausea and vomiting	3,145	Olanzapine-containing regimens	mimxylchqo(iwbxkpbxqi) = rtfsiovqrv ykpsuqwumv (ijyuyemyau ) View more	Positive	29 May 2026
				NK1-based triple therapy	mimxylchqo(iwbxkpbxqi) = hvsweaefgy ykpsuqwumv (ijyuyemyau ) View more
INPHOG-SUPP-22-03 (ASCO2026)	Phase 3	Chemotherapy-induced nausea and vomiting	310	Dexamethasone, palonosetron, and fosaprepitant	emhjzznuqx(ckujktihhz) = skbgnayymi ucqkbqrwmy (azlnuiyhzi ) View more	Non-inferior	29 May 2026
				Olanzapine, palonosetron, and fosaprepitant	emhjzznuqx(ckujktihhz) = vjdiirutsb ucqkbqrwmy (azlnuiyhzi ) View more